SpringTide Ventures

www.springtide.com

VCMatch tracks SpringTide Ventures as an investor focused on Digital Health, Medtech, and Biotech companies, Seed and Series A rounds, United States and Global / Emerging Markets markets, and $4m to $20m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$4m to $20m

Stages

Seed, Series A

Focus Areas

Digital Health, Medtech, Biotech

Geography

United States and Global / emerging markets

Investment Thesis

SpringTide invests early in health-tech companies that deliver patient-centered, accessible, affordable care by favoring integrated, end-to-end solutions and deep, company-level research. They stress that successful healthcare companies must solve root problems within the constraints of the US system (reimbursement, regulation, sales cycles) and prefer ventures that can demonstrate pathways to sustainable clinical and commercial traction—often by selling to outpatient and underserved markets or by importing innovations from resource‑constrained environments.

Is SpringTide Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

SpringTide Ventures is most relevant for founders raising Seed and Series A rounds in Digital Health, Medtech, Biotech, and Healthtech, especially across United States and Global / emerging markets, with public check-size signals around $4m to $20m.

Focus statement

SpringTide "lead[s] early-stage financings for tomorrow's greatest healthcare companies," with a focus on health-tech that improves accessibility, quality, and affordability (telehealth, remote monitoring, AI-powered medtech, Smart EHR UI, and innovations that serve underserved or resource-constrained patient populations).

Value Add

"n of 1" research approach—"carefully examining one company at a time" to generate deep, causal insight rather than broad surveys
Preference for end-to-end, integrated solutions rather than point software products (focus on companies that control clinical volume and workflows)
Willingness to source and back "reverse innovations" from resource-constrained or overlooked geographies and scale them into larger markets
Operationally pragmatic thesis—invests in companies that understand reimbursement, buy‑side complexity, and route-to-market (e.g., outpatient clinics, pharmacies)
Active sector specialization across clinical integration, telehealth infrastructure, remote patient monitoring, digital pathology and Smart EHR UI